Are the innate and adaptive immune systems setting hypertension on fire?

Pharmacological Research

Volumn 117, Issue , 2017, Pages 377-393

  Bomfim, Gisele F ^a   Rodrigues, Fernanda Luciano ^b   Carneiro, Fernando S ^b  

^a FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

DAMPs; Hypertension; Immune system; NLRP3; Toll like receptors; Vascular inflammation

Indexed keywords

BIOLOGICAL FACTOR; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CHEMOKINE; CRYOPYRIN; CYTOKINE; DAMAGE ASSOCIATED MOLECULAR PATTERN; INFLAMMASOME; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CYTOKINE RELEASE; DISEASE COURSE; GAMMA DELTA T LYMPHOCYTE; HEART; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INNATE IMMUNITY; KIDNEY; LYMPHOCYTE ACTIVATION; MORBIDITY; MORTALITY; NERVE ENDING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; REVIEW; SEX DIFFERENCE; TH1 CELL; TH17 CELL; VASCULAR DISEASE; VASCULITIS; ANIMAL; IMMUNOLOGY; INFLAMMATION;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-PRESENTING CELLS; HUMANS; HYPERTENSION; IMMUNITY, INNATE; INFLAMMATION;

EID: 85009876198     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.01.010     Document Type: Review

References (237)

1. [1] Matzinger, P., The danger model: a renewed sense of self. Science 296:5566 (2002), 301–305.
2. [2] Kawasaki, T., Kawai, T., Toll-like receptor signaling pathways. Front. Immunol., 5, 2014, 461.
3. [3] Schroder, K., Tschopp, J., The inflammasomes. Cell 140:6 (2010), 821–832.
4. [4] Wenzel, P., Knorr, M., Kossmann, S., Stratmann, J., Hausding, M., Schuhmacher, S., Munzel, T., Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 124:12 (2011), 1370–1381.
5. [5] De Ciuceis, C., Amiri, F., Brassard, P., Endemann, D.H., Touyz, R.M., Schiffrin, E.L., Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler. Thromb. Vasc. Biol. 25:10 (2005), 2106–2113.
6. [6] Ko, E.A., Amiri, F., Pandey, N.R., Javeshghani, D., Leibovitz, E., Touyz, R.M., Schiffrin, E.L., Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. Am. J. Physiol. Heart. Circ. Physiol. 292:4 (2007), H1789–H1795.
7. [7] Rickard, A.J., Morgan, J., Tesch, G., Funder, J.W., Fuller, P.J., Young, M.J., Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54:3 (2009), 537–543.
8. [8] Machnik, A., Neuhofer, W., Jantsch, J., Dahlmann, A., Tammela, T., Machura, K., Titze, J., Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat. Med. 15:5 (2009), 545–552.
9. [9] Liu, X., Zhang, Q., Wu, H., Du, H., Liu, L., Shi, H., Niu, K., Blood neutrophil to lymphocyte ratio as a predictor of hypertension. Am. J. Hypertens. 28:11 (2015), 1339–1346.
10. [10] Regal, J.F., Lillegard, K.E., Bauer, A.J., Elmquist, B.J., Loeks-Johnson, A.C., Gilbert, J.S., Neutrophil depletion attenuates placental ischemia-induced hypertension in the rat. PLoS One, 10(7), 2015, e0132063.
11. [11] Kirabo, A., Fontana, V., de Faria, A.P., Loperena, R., Galindo, C.L., Wu, J., Harrison, D.G., DC isoketal-modified proteins activate T cells and promote hypertension. J. Clin. Invest. 124:10 (2014), 4642–4656.
12. [12] Wu, J., Saleh, M.A., Kirabo, A., Itani, H.A., Montaniel, K.R., Xiao, L., Harrison, D.G., Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J. Clin. Invest., 126(4), 2016, 1607.
13. [13] Harrison, D., Sy 17-2 inflammation, immunity and hypertension. J. Hypertens., 34(Suppl. 1), 2016, e535 ISH 2016 Abstract Book.
14. [14] Kumar, H., Kawai, T., Akira, S., Pathogen recognition in the innate immune response. Biochem. J 420:1 (2009), 1–16.
15. [15] Medzhitov, R., Janeway, C.A. Jr., Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9:1 (1997), 4–9.
16. [16] Fearon, D.T., Locksley, R.M., The instructive role of innate immunity in the acquired immune response. Science 272:5258 (1996), 50–53.
17. [17] Vallabhapurapu, S., Karin, M., Regulation and function of NF-kappa B transcription factors in the immune system. Annu. Rev. Immunol. 27 (2009), 693–733.
18. [18] Battistini, A., Interferon regulatory factors in hematopoietic cell differentiation and immune regulation. J. Interf. Cytok. Res. 29:12 (2009), 765–779.
19. [19] Sheedy, F.J., O'Neill, L.A., The Troll in Toll: Mal and Tram as bridges for TLR2 and TLR4 signaling. J. Leukoc. Biol. 82:2 (2007), 196–203.
20. [20] Akira, S., Uematsu, S., Takeuchi, O., Pathogen recognition and innate immunity. Cell 124:4 (2006), 783–801.
21. [21] Barton, G.M., Kagan, J.C., Medzhitov, R., Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 7:1 (2006), 49–56.
22. [22] Latz, E., Schoenemeyer, A., Visintin, A., Fitzgerald, K.A., Monks, B.G., Knetter, C.F., Golenbock, D.T., TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5:2 (2004), 190–198.
23. [23] Nishiya, T., Kajita, E., Miwa, S., Defranco, A.L., TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J. Biol. Chem. 280:44 (2005), 37107–37117.
24. [24] Underhill, D.M., Ozinsky, A., Hajjar, A.M., Stevens, A., Wilson, C.B., Bassetti, M., Aderem, A., The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401:6755 (1999), 811–815.
25. [25] Lauw, F.N., Caffrey, D.R., Golenbock, D.T., Of mice and man: TLR11 (finally) finds profilin. Trends Immunol. 26:10 (2005), 509–511.
26. [26] Zhang, D., Zhang, G., Hayden, M.S., Greenblatt, M.B., Bussey, C., Flavell, R.A., Ghosh, S., A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303:5663 (2004), 1522–1526.
27. [27] Gay, N.J., Keith, F.J., Drosophila Toll and IL-1 receptor. Nature 351:6325 (1991), 355–356.
28. [28] Horng, T., Barton, G.M., Flavell, R.A., Medzhitov, R., The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420:6913 (2002), 329–333.
29. [29] Honda, K., Yanai, H., Mizutani, T., Negishi, H., Shimada, N., Suzuki, N., Taniguchi, T., Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 101:43 (2004), 15416–15421.
30. [30] Negishi, H., Fujita, Y., Yanai, H., Sakaguchi, S., Ouyang, X., Shinohara, M., Honda, K., Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. Proc. Natl. Acad. Sci. U. S. A. 103:41 (2006), 15136–15141.
31. [31] Takaoka, A., Yanai, H., Kondo, S., Duncan, G., Negishi, H., Mizutani, T., Taniguchi, T., Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:7030 (2005), 243–249.
32. [32] Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H., Akira, S., Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301:5633 (2003), 640–643.
33. [33] Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., Akira, S., Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169:12 (2002), 6668–6672.
34. [34] Kagan, J.C., Su, T., Horng, T., Chow, A., Akira, S., Medzhitov, R., TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 9:4 (2008), 361–368.
35. [35] Liew, F.Y., Xu, D., Brint, E.K., O'Neill, L.A., Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5:6 (2005), 446–458.
36. [36] Takeda, K., Akira, S., Toll-like receptors in innate immunity. Int. Immunol. 17:1 (2005), 1–14.
37. [37] Rifkin, I.R., Leadbetter, E.A., Busconi, L., Viglianti, G., Marshak-Rothstein, A., Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204 (2005), 27–42.
38. [38] Brentano, F., Kyburz, D., Schorr, O., Gay, R., Gay, S., The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell. Immunol. 233:2 (2005), 90–96.
39. [39] Yu, L., Wang, L., Chen, S., Endogenous toll-like receptor ligands and their biological significance. J. Cell. Mol. Med. 14:11 (2010), 2592–2603.
40. [40] Sollinger, D., Eissler, R., Lorenz, S., Strand, S., Chmielewski, S., Aoqui, C., Baumann, M., Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in L-NAME-induced hypertension. Cardiovasc. Res. 101:3 (2014), 464–472.
41. [41] McCarthy, C.G., Goulopoulou, S., Wenceslau, C.F., Spitler, K., Matsumoto, T., Webb, R.C., Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am. J. Physiol. Heart Circ. Physiol. 306:2 (2014), H184–H196.
42. [42] Lim, S.S., Vos, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H., Memish, Z.A., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2224–2260.
43. [43] Leibowitz, A., Schiffrin, E.L., Immune mechanisms in hypertension. Curr. Hypertens. Rep. 13:6 (2011), 465–472.
44. [44] Caillon, A., Schiffrin, E.L., Role of inflammation and immunity in hypertension: recent epidemiological, laboratory, and clinical evidence. Curr. Hypertens. Rep., 18(3), 2016, 21.
45. [45] Marques, R., Boneca, I.G., Expression and functional importance of innate immune receptors by intestinal epithelial cells. Cell. Mol. Life Scie.: CMLS 68:22 (2011), 3661–3673.
46. [46] Garrafa, E., Imberti, L., Tiberio, G., Prandini, A., Giulini, S.M., Caimi, L., Heterogeneous expression of toll-like receptors in lymphatic endothelial cells derived from different tissues. Immunol. Cell Biol. 89:3 (2011), 475–481.
47. [47] de Graaf, R., Kloppenburg, G., Kitslaar, P.J., Bruggeman, C.A., Stassen, F., Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect. 8:7 (2006), 1859–1865.
48. [48] Liu, N., Liu, J., Ji, Y., Lu, P., Toll-like receptor 4 signaling mediates inflammatory activation induced by C-reactive protein in vascular smooth muscle cells. Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 25:4–5 (2010), 467–476.
49. [49] Bsibsi, M., Ravid, R., Gveric, D., van Noort, J.M., Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 61:11 (2002), 1013–1021.
50. [50] Tang, S.C., Lathia, J.D., Selvaraj, P.K., Jo, D.G., Mughal, M.R., Cheng, A., Mattson, M.P., Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 213:1 (2008), 114–121.
51. [51] Matzinger, P., Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12 (1994), 991–1045.
52. [52] Foster, S.L., Medzhitov, R., Gene-specific control of the TLR-induced inflammatory response. Clin. Immunol. 130:1 (2009), 7–15.
53. [53] Netea, M.G., Wijmenga, C., O'Neill, L.A., Genetic variation in Toll-like receptors and disease susceptibility. Nat. Immunol. 13:6 (2012), 535–542.
54. [54] Ameziane, N., Beillat, T., Verpillat, P., Chollet-Martin, S., Aumont, M.C., Seknadji, P., de Prost, D., Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. 23:12 (2003), e61–4.
55. [55] Bomfim, G.F., Dos Santos, R.A., Oliveira, M.A., Giachini, F.R., Akamine, E.H., Tostes, R.C., Carvalho, M.H., Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin. Sci. 122:11 (2012), 535–543.
56. [56] Eissler, R., Schmaderer, C., Rusai, K., Kuhne, L., Sollinger, D., Lahmer, T., Baumann, M., Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens. Res. 34:5 (2011), 551–558.
57. [57] Dange, R.B., Agarwal, D., Teruyama, R., Francis, J., Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension. J. Neuroinflammation, 12, 2015, 31.
58. [58] Harwani, S.C., Chapleau, M.W., Legge, K.L., Ballas, Z.K., Abboud, F.M., Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension. Circ. Res. 111:9 (2012), 1190–1197.
59. [59] McCarthy, C.G., Wenceslau, C.F., Goulopoulou, S., Ogbi, S., Baban, B., Sullivan, J.C., Webb, R.C., Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc. Res. 107:1 (2015), 119–130.
60. [60] Ahn, K.O., Lim, S.W., Li, C., Yang, H.J., Ghee, J.Y., Kim, J.Y., Yang, C.W., Influence of angiotensin II on expression of toll-like receptor 2 and maturation of dendritic cells in chronic cyclosporine nephropathy. Transplantation 83:7 (2007), 938–947.
61. [61] De Batista, P.R., Palacios, R., Martin, A., Hernanz, R., Medici, C.T., Silva, M.A., Alonso, M.J., Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PLoS One, 9(8), 2014, e104020.
62. [62] Hernanz, R., Martinez-Revelles, S., Palacios, R., Martin, A., Cachofeiro, V., Aguado, A., Alonso, M.J., Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br. J. Pharmacol. 172:12 (2015), 3159–3176.
63. [63] Ding, Z., Liu, S., Wang, X., Khaidakov, M., Fan, Y., Deng, X., Mehta, J.L., Lectin-like oxidized low-density lipoprotein receptor-1 regulates autophagy and Toll-like receptor 4 in the brain of hypertensive mice. J. Hypertens. 33:3 (2015), 525–533 discussion 533.
64. [64] Dange, R.B., Agarwal, D., Masson, G.S., Vila, J., Wilson, B., Nair, A., Francis, J., Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc. Res. 103:1 (2014), 17–27.
65. [65] Kenny, E.F., O'Neill, L.A., Signalling adaptors used by Toll-like receptors: an update. Cytokine 43:3 (2008), 342–349.
66. [66] Singh, M.V., Cicha, M.Z., Meyerholz, D.K., Chapleau, M.W., Abboud, F.M., Dual activation of TRIF and MyD88 adaptor proteins by angiotensin II evokes opposing effects on pressure, cardiac hypertrophy, and inflammatory gene expression. Hypertension 66:3 (2015), 647–656.
67. [67] Bobek, G., Surmon, L., Mirabito, K.M., Makris, A., Hennessy, A., Placental regulation of inflammation and hypoxia after TNF-alpha infusion in mice. Am. J. Reprod. Immunol. 74:5 (2015), 407–418.
68. [68] Chatterjee, P., Chiasson, V.L., Kopriva, S.E., Young, K.J., Chatterjee, V., Jones, K.A., Mitchell, B.M., Interleukin 10 deficiency exacerbates toll-like receptor 3-induced preeclampsia-like symptoms in mice. Hypertension 58:3 (2011), 489–496.
69. [69] Tinsley, J.H., Chiasson, V.L., Mahajan, A., Young, K.J., Mitchell, B.M., Toll-like receptor 3 activation during pregnancy elicits preeclampsia-like symptoms in rats. Am. J. Hypertens. 22:12 (2009), 1314–1319.
70. [70] Singh, M.V., Abboud, F.M., Toll-like receptors and hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307:5 (2014), R501–4.
71. [71] Kim, Y.M., Romero, R., Oh, S.Y., Kim, C.J., Kilburn, B.A., Armant, D.R., Mor, G., Toll-like receptor 4: a potential link between danger signals, the innate immune system, and preeclampsia?. Am. J. Obst. Gynecol. 193:3 Pt 2 (2005), 921–927.
72. [72] Chatterjee, P., Weaver, L.E., Doersch, K.M., Kopriva, S.E., Chiasson, V.L., Allen, S.J., Mitchell, B.M., Placental Toll-like receptor 3 and Toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice. PLoS One, 7(7), 2012, e41884.
73. [73] Goulopoulou, S., Matsumoto, T., Bomfim, G.F., Webb, R.C., Toll-like receptor 9 activation: a novel mechanism linking placenta-derived mitochondrial DNA and vascular dysfunction in pre-eclampsia. Clin. Sci. 123:7 (2012), 429–435.
74. [74] Goulopoulou, S., Wenceslau, C.F., McCarthy, C.G., Matsumoto, T., Webb, R.C., Exposure to stimulatory CpG oligonucleotides during gestation induces maternal hypertension and excess vasoconstriction in pregnant rats. Am. J. Physiol. Heart Circ. Physiol. 310:8 (2016), H1015–25.
75. [75] Zhang, Y., Peng, W., Ao, X., Dai, H., Yuan, L., Huang, X., Zhou, Q., TAK-242, a toll-like receptor 4 antagonist protects against aldosterone-induced cardiac and renal injury. PLoS One, 10(11), 2015, e0142456.
76. [76] Summers, S.A., Steinmetz, O.M., Ooi, J.D., Gan, P.Y., O'Sullivan, K.M., Visvanathan, K., Holdsworth, S.R., Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis. Am. J. Pathol. 177:5 (2010), 2234–2244.
77. [77] Paulus, P., Rupprecht, K., Baer, P., Obermuller, N., Penzkofer, D., Reissig, C., Urbschat, A., The early activation of toll-like receptor (TLR)-3 initiates kidney injury after ischemia and reperfusion. PLoS One, 9(4), 2014, e94366.
78. [78] Lin, M., Tang, S.C., Toll-like receptors: sensing and reacting to diabetic injury in the kidney. Nephrol. Dial. Transplant. 29:4 (2014), 746–754.
79. [79] Liang, C.F., Liu, J.T., Wang, Y., Xu, A., Vanhoutte, P.M., Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4. Arterioscler. Thromb. Vasc. Biol. 33:4 (2013), 777–784.
80. [80] Huang, Y.Y., Su, W., Zhu, Z.W., Tang, L., Hu, X.Q., Zhou, S.H., Li, J., Elevated serum HMGB1 in pulmonary arterial hypertension secondary to congenital heart disease. Vascul. Pharmacol., 2016.
81. [81] Zabini, D., Crnkovic, S., Xu, H., Tscherner, M., Ghanim, B., Klepetko, W., Marsh, L.M., High-mobility group box-1 induces vascular remodelling processes via c-Jun activation. J. Cell. Mol. Med. 19:5 (2015), 1151–1161.
82. [82] Bauer, E.M., Shapiro, R., Zheng, H., Ahmad, F., Ishizawar, D., Comhair, S.A., Bauer, P.M., High mobility group Box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol. Med. 18 (2012), 1509–1518.
83. [83] Guiducci, C., Gong, M., Xu, Z., Gill, M., Chaussabel, D., Meeker, T., Barrat, F.J., TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465:7300 (2010), 937–941.
84. [84] De Miguel, C., Rudemiller, N.P., Abais, J.M., Mattson, D.L., Inflammation and hypertension: new understandings and potential therapeutic targets. Curr. Hypertens. Rep., 17(1), 2015, 507.
85. [85] Vijay-Kumar, M., Aitken, J.D., Carvalho, F.A., Cullender, T.C., Mwangi, S., Srinivasan, S., Gewirtz, A.T., Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328:5975 (2010), 228–231.
86. [86] Goulopoulou, S., McCarthy, C.G., Webb, R.C., Toll-like receptors in the vascular system: sensing the dangers within. Pharmacol. Rev. 68:1 (2016), 142–167.
87. [87] Qiao, H., Zhang, X., Zhu, C., Dong, L., Wang, L., Zhang, X., Cao, X., Luteolin downregulates TLR4, TLR5, NF-kappaB and p-p38MAPK expression, upregulates the p-ERK expression, and protects rat brains against focal ischemia. Brain Res. 1448 (2012), 71–81.
88. [88] Dajnowiec, D., Langille, B.L., Arterial adaptations to chronic changes in haemodynamic function: coupling vasomotor tone to structural remodelling. Clin. Sci. 113:1 (2007), 15–23.
89. [89] Sprague, A.H., Khalil, R.A., Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol. 78:6 (2009), 539–552.
90. [90] Pryshchep, O., Ma-Krupa, W., Younge, B.R., Goronzy, J.J., Weyand, C.M., Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118:12 (2008), 1276–1284.
91. [91] Wang, Y., Song, E., Bai, B., Vanhoutte, P.M., Toll-like receptors mediating vascular malfunction: lessons from receptor subtypes. Pharmacol. Ther. 158 (2016), 91–100.
92. [92] Cartwright, N., McMaster, S.K., Sorrentino, R., Paul-Clark, M., Sriskandan, S., Ryffel, B., Mitchell, J.A., Elucidation of toll-like receptor and adapter protein signaling in vascular dysfunction induced by gram-positive Staphylococcus aureus or gram-negative Escherichia coli. Shock 27:1 (2007), 40–47.
93. [93] Marvar, P.J., Thabet, S.R., Guzik, T.J., Lob, H.E., McCann, L.A., Weyand, C., Harrison, D.G., Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ. Res. 107:2 (2010), 263–270.
94. [94] Bonizzi, G., Karin, M., The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25:6 (2004), 280–288.
95. [95] McAllister-Lucas, L.M., Jin, X., Gu, S., Siu, K., McDonnell, S., Ruland, J., Lucas, P.C., The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J. Biol. Chem. 285:34 (2010), 25880–25884.
96. [96] Takahashi, M., Suzuki, E., Takeda, R., Oba, S., Nishimatsu, H., Kimura, K., Hirata, Y., Angiotensin II and tumor necrosis factor-alpha synergistically promote monocyte chemoattractant protein-1 expression: roles of NF-kappaB, p38, and reactive oxygen species. Am. J. Physiol. Heart Circ. Physiol. 294:6 (2008), H2879–88.
97. [97] Valente, A.J., Yoshida, T., Murthy, S.N., Sakamuri, S.S., Katsuyama, M., Clark, R.A., Chandrasekar, B., Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am. J. Physiol. Heart Circ. Physiol. 303:3 (2012), H282–H2966.
98. [98] Muller, D.N., Dechend, R., Mervaala, E.M., Park, J.K., Schmidt, F., Fiebeler, A., Luft, F.C., NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35:1 Pt 2 (2000), 193–201.
99. [99] Rodriguez-Iturbe, B., Ferrebuz, A., Vanegas, V., Quiroz, Y., Mezzano, S., Vaziri, N.D., Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 315:1 (2005), 51–57.
100. [100] Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K., Cobb, M.H., Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22:2 (2001), 153–183.
101. [101] Kim, S., Iwao, H., Stress and vascular responses: mitogen-activated protein kinases and activator protein-1 as promising therapeutic targets of vascular remodeling. J. Pharmacol. Sci. 91:3 (2003), 177–181.
102. [102] Kim, J., Lee, Y.R., Lee, C.H., Choi, W.H., Lee, C.K., Kim, J., Kim, B., Mitogen-activated protein kinase contributes to elevated basal tone in aortic smooth muscle from hypertensive rats. Eur. J. Pharmacol. 514:2–3 (2005), 209–215.
103. [103] Giachini, F.R., Sullivan, J.C., Lima, V.V., Carneiro, F.S., Fortes, Z.B., Pollock, D.M., Tostes, R.C., Extracellular signal-regulated kinase 1/2 activation, via downregulation of mitogen-activated protein kinase phosphatase 1, mediates sex differences in desoxycorticosterone acetate-salt hypertension vascular reactivity. Hypertension 55:1 (2010), 172–179.
104. [104] Touyz, R.M., El Mabrouk, M., He, G., Wu, X.H., Schiffrin, E.L., Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin II-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Circ. Res. 84:5 (1999), 505–515.
105. [105] Touyz, R.M., He, G., Deng, L.Y., Schiffrin, E.L., Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance arteries. Circulation 99:3 (1999), 392–399.
106. [106] Bao, W., Behm, D.J., Nerurkar, S.S., Ao, Z., Bentley, R., Mirabile, R.C., Yue, T.L., Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J. Cardiovasc. Pharmacol. 49:6 (2007), 362–368.
107. [107] Behr, T.M., Nerurkar, S.S., Nelson, A.H., Coatney, R.W., Woods, T.N., Sulpizio, A., Willette, R.N., Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104:11 (2001), 1292–1298.
108. [108] Olzinski, A.R., McCafferty, T.A., Zhao, S.Q., Behm, D.J., Eybye, M.E., Maniscalco, K., Willette, R.N., Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. Cardiovasc. Res. 66:1 (2005), 170–178.
109. [109] Mullick, A.E., Soldau, K., Kiosses, W.B., Tobias, T.A., Bell, P.S. 3rd, Curtiss, L.K., Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J. Exp. Med. 205:2 (2008), 373–383.
110. [110] Speer, T., Rohrer, L., Blyszczuk, P., Shroff, R., Kuschnerus, K., Krankel, N., Landmesser, U., Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38:4 (2013), 754–768.
111. [111] Shishido, T., Nozaki, N., Takahashi, H., Arimoto, T., Niizeki, T., Koyama, Y., Kubota, I., Central role of endogenous Toll-like receptor-2 activation in regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury. Biochem. Biophys. Res. Commun. 345:4 (2006), 1446–1453.
112. [112] Cole, J.E., Navin, T.J., Cross, A.J., Goddard, M.E., Alexopoulou, L., Mitra, A.T., Monaco, C., Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc. Natl. Acad. Sci. U. S. A. 108:6 (2011), 2372–2377.
113. [113] Martin-Rodriguez, S., Caballo, C., Gutierrez, G., Vera, M., Cruzado, J.M., Cases, A., Diaz-Ricart, M., TLR4 and NALP3 inflammasome in the development of endothelial dysfunction in uraemia. Eur. J. Clin. Invest. 45:2 (2015), 160–169.
114. [114] Kim, F., Pham, M., Luttrell, I., Bannerman, D.D., Tupper, J., Thaler, J., Schwartz, M.W., Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ. Res. 100:11 (2007), 1589–1596.
115. [115] Li, W., Sama, A.E., Wang, H., Role of HMGB1 in cardiovascular diseases. Curr. Opin. Pharmacol. 6:2 (2006), 130–135.
116. [116] Nakamura, M., Shimizu, Y., Sato, Y., Miyazaki, Y., Satoh, T., Mizuno, M., Furusako, S., Toll-like receptor 4 signal transduction inhibitor, M62812, suppresses endothelial cell and leukocyte activation and prevents lethal septic shock in mice. Eur. J. Pharmacol. 569:3 (2007), 237–243.
117. [117] Kolek, M.J., Carlquist, J.F., Muhlestein, J.B., Whiting, B.M., Horne, B.D., Bair, T.L., Anderson, J.L., Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am. Heart J. 148:6 (2004), 1034–1040.
118. [118] Cipolla, M.J., Houston, E.M., Kraig, R.P., Bonney, E.A., Differential effects of low-dose endotoxin on the cerebral circulation during pregnancy. Reprod. Sci. 18:12 (2011), 1211–1221.
119. [119] Ji, Y., Liu, J., Wang, Z., Liu, N., Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 23:4–6 (2009), 265–276.
120. [120] Nakashima, T., Umemoto, S., Yoshimura, K., Matsuda, S., Itoh, S., Murata, T., Matsuzaki, M., TLR4 is a critical regulator of angiotensin II-induced vascular remodeling: the roles of extracellular SOD and NADPH oxidase. Hypertens. Res. 38:10 (2015), 649–655.
121. [121] Latz, E., The inflammasomes: mechanisms of activation and function. Curr. Opin. Immunol. 22:1 (2010), 28–33.
122. [122] Martinon, F., Gaide, O., Petrilli, V., Mayor, A., Tschopp, J., NALP inflammasomes: a central role in innate immunity. Semin. Immunopathol. 29:3 (2007), 213–229.
123. [123] Harton, J.A., Linhoff, M.W., Zhang, J., Ting, J.P., Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J. Immunol. 169:8 (2002), 4088–4093.
124. [124] Kanneganti, T.D., Lamkanfi, M., Nunez, G., Intracellular NOD-like receptors in host defense and disease. Immunity 27:4 (2007), 549–559.
125. [125] Inohara, N., Nunez, G., NODs: intracellular proteins involved in inflammation and apoptosis. Nat. Rev. Immunol. 3:5 (2003), 371–382.
126. [126] Kersse, K., Bertrand, M.J., Lamkanfi, M., Vandenabeele, P., NOD-like receptors and the innate immune system: coping with danger, damage and death. Cytokine Growth Factor Rev. 22:5-6 (2011), 257–276.
127. [127] Inohara, N., Koseki, T., del Peso, L., Hu, Y., Yee, C., Chen, S., Nunez, G., Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J. Biol. Chem. 274:21 (1999), 14560–14567.
128. [128] Agostini, L., Martinon, F., Burns, K., McDermott, M.F., Hawkins, P.N., Tschopp, J., NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20:3 (2004), 319–325.
129. [129] Martinon, F., Burns, K., Tschopp, J., The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10:2 (2002), 417–426.
130. [130] Martinon, F., Tschopp, J., Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 14:1 (2007), 10–22.
131. [131] Kostura, M.J., Tocci, M.J., Limjuco, G., Chin, J., Cameron, P., Hillman, A.G., Schmidt, J.A., Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc. Natl. Acad. Sci. U. S. A. 86:14 (1989), 5227–5231.
132. [132] Black, R.A., Kronheim, S.R., Merriam, J.E., March, C.J., Hopp, T.P., A pre-aspartate-specific protease from human-leukocytes that cleaves pro-interleukin-1-beta. J. Biol. Chem. 264:10 (1989), 5323–5326.
133. [133] Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C., et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80:3 (1995), 401–411.
134. [134] Kuida, K., Lippke, J.A., Ku, G., Harding, M.W., Livingston, D.J., Su, M.S., Flavell, R.A., Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267:5206 (1995), 2000–2003.
135. [135] Thelemann, C., Haller, S., Blyszczuk, P., Kania, G., Rosa, M., Eriksson, U., Acha-Orbea, H., Absence of nonhematopoietic MHC class II expression protects mice from experimental autoimmune myocarditis. Eur. J. Immunol. 46:3 (2016), 656–664.
136. [136] Li, W.M., Liu, W., Gao, C., Zhou, B.G., Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats. Immunol. Cell Biol. 84:3 (2006), 274–280.
137. [137] Gouraud, S.S., Waki, H., Bhuiyan, M.E., Takagishi, M., Kohsaka, A., Maeda, M., Increased anti-apoptotic conditions in the nucleus tractus solitarii of spontaneously hypertensive rat. Auton. Neurosci. 162:1–2 (2011), 15–23.
138. [138] Cartwright, N., Murch, O., McMaster, S.K., Paul-Clark, M.J., van Heel, D.A., Ryffel, B., Mitchell, J.A., Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Am. J. Respir. Crit. Care Med. 175:6 (2007), 595–603.
139. [139] Nishio, H., Kanno, S., Onoyama, S., Ikeda, K., Tanaka, T., Kusuhara, K., Hara, T., Nod1 ligands induce site-specific vascular inflammation. Arterioscler. Thromb. Vasc. Biol. 31:5 (2011), 1093–1099.
140. [140] Fernandez-Velasco, M., Prieto, P., Terron, V., Benito, G., Flores, J.M., Delgado, C., Bosca, L., NOD1 activation induces cardiac dysfunction and modulates cardiac fibrosis and cardiomyocyte apoptosis. PLoS One, 7(9), 2012, e45260.
141. [141] Yang, H., Li, N., Song, L.N., Wang, L., Tian, C., Tang, C.S., Wang, H.X., Activation of NOD1 by DAP contributes to myocardial ischemia/reperfusion injury via multiple signaling pathways. Apoptosis 20:4 (2015), 512–522.
142. [142] Gu, C.C., Hunt, S.C., Kardia, S., Turner, S.T., Chakravarti, A., Schork, N., Rao, D.C., An investigation of genome-wide associations of hypertension with microsatellite markers in the family blood pressure program (FBPP). Hum. Genet. 121:5 (2007), 577–590.
143. [143] Galluzzo, S., Patti, G., Dicuonzo, G., Di Sciascio, G., Tonini, G., Ferraro, E., Angeletti, S., Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study. Hum. Immunol. 72:8 (2011), 636–640.
144. [144] Li, X., Li, F.L., Chu, Y.L., Wang, X.J., Zhang, H.Y., Hu, Y.Y., Yi, F., NOD2 deficiency protects against cardiac remodeling after myocardial infarction in mice. Cell. Physiol. Biochem. 32:6 (2013), 1857–1866.
145. [145] Liu, Y., Yang, H., Liu, L.X., Yan, W., Guo, H.J., Li, W.J., Wang, H.X., NOD2 contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and inflammation. Life Sci. 149 (2016), 10–17.
146. [146] Zong, J., Salim, M., Zhou, H., Bian, Z.Y., Dai, J., Yuan, Y., Tang, Q.Z., NOD2 deletion promotes cardiac hypertrophy and fibrosis induced by pressure overload. Lab. Invest. 93:10 (2013), 1128–1136.
147. [147] Kwon, M.Y., Liu, X., Lee, S.J., Kang, Y.H., Choi, A.M., Lee, K.U., Chung, S.W., Nucleotide-binding oligomerization domain protein 2 deficiency enhances neointimal formation in response to vascular injury. Arterioscler. Thromb. Vasc. Biol. 31:11 (2011), 2441–2447.
148. [148] Herrera, V.L., Bagamasbad, P., Didishvili, T., Decano, J.L., Ruiz-Opazo, N., Overlapping genes in Nalp6/PYPAF5 locus encode two V2-type vasopressin isoreceptors: angiotensin-vasopressin receptor (AVR) and non-AVR. Physiol. Genom. 34:1 (2008), 65–77.
149. [149] Ruiz-Opazo, N., Lopez, L.V., Herrera, V.L., The dual AngII/AVP receptor gene N119S/C163R variant exhibits sodium-induced dysfunction and cosegregates with salt-sensitive hypertension in the Dahl salt-sensitive hypertensive rat model. Mol. Med. 8:1 (2002), 24–32.
150. [150] Glorioso, N., Herrera, V.L., Didishvili, T., Ortu, M.F., Zaninello, R., Fresu, G., Ruiz-Opazo, N., Sex-specific effects of NLRP6/AVR and ADM loci on susceptibility to essential hypertension in a Sardinian population. PLoS One, 8(10), 2013, e77562.
151. [151] Omi, T., Kumada, M., Kamesaki, T., Okuda, H., Munkhtulga, L., Yanagisawa, Y., Iwamoto, S., An intronic variable number of tandem repeat polymorphisms of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene modifies gene expression and is associated with essential hypertension. Eur. J. Hum. Genet. 14:12 (2006), 1295–1305.
152. [152] Kunnas, T., Maatta, K., Nikkari, S.T., NLR family pyrin domain containing 3 (NLRP3) inflammasome gene polymorphism rs7512998 (C > T) predicts aging-related increase of blood pressure, the TAMRISK study. Immunol. Ageing, 12, 2015, 19.
153. [153] Bruder-Nascimento, T., Ferreira, N.S., Zanotto, C.Z., Ramalho, F.N., Pequeno, I.O., Olivon, V.C., Tostes, R.C., NLRP3 inflammasome mediates aldosterone-induced vascular damage. Circulation, 2016, 10.1161/CIRCULATIONAHA.116.024369.
154. [154] Zhu, Z., Yan, J., Geng, C., Wang, D., Li, C., Feng, S., Wang, H., A polymorphism within the 3'UTR of NLRP3 is associated with susceptibility for ischemic stroke in chinese population. Cell. Mol. Neurobiol. 36:6 (2016), 981–988.
155. [155] Rahamthulla, S., Narasaiah, K., Aaron, B.W., Activation of inflammasome in pulmonary arterial hypertension, C57. Pulmonary Hypertension: Biomarkers, Genetics, And Genomics: Insights Into Pathogenesis, 2010, American Thoracic Society, A4865.
156. [156] Matias, M.L., Romao, M., Weel, I.C., Ribeiro, V.R., Nunes, P.R., Borges, V.T., Peracoli, M.T., Endogenous and uric acid-induced activation of NLRP3 inflammasome in pregnant women with preeclampsia. PLoS One, 10(6), 2015, e0129095.
157. [157] Chen, H., Lu, Z.Z., Wei, H., Han, C., Induction of ICE and inhibition of c-fos, jun D and zif 268 in 12-month old spontaneously hypertensive rats. Life Sci. 61:2 (1997), PL27–PL31.
158. [158] Wang, Q., So, A., Nussberger, J., Tschopp, J., Burnier, M., Impact of NLRP3 inflammasome on the development of hypertension and renal and cardiac hypertrophy in 2K1C and doca/salt micE. Kidney Res. Clin. Pract., 31(2), 2012, A83.
159. [159] Krishnan, S.M., Dowling, J.K., Ling, Y.H., Diep, H., Chan, C.T., Ferens, D., Drummond, G.R., Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice. Br. J. Pharmacol. 173:4 (2016), 752–765.
160. [160] Doi, T., Doi, S., Nakashima, A., Ueno, T., Yokoyama, Y., Kohno, N., Masaki, T., Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats. PLoS One, 9(4), 2014, e93513.
161. [161] Qi, J., Yu, X.J., Shi, X.L., Gao, H.L., Yi, Q.Y., Tan, H., Kang, Y.M., NF-kappa B blockade in hypothalamic paraventricular nucleus inhibits high-salt-induced hypertension through NLRP3 and caspase-1. Cardiovasc. Toxicol., 2015.
162. [162] Zhu, Q., Li, X.X., Wang, W., Hu, J., Li, P.L., Conley, S.M., Li, N., Mesenchymal stem cell transplantation inhibited high salt-induced activation of the NLRP3 inflammasome in the renal medulla in Dahl S rats. Am. J. Physiol. Renal Physiol., 2015, 2016 Ajprenal 00344.
163. [163] Xia, M., Abais, J.M., Koka, S., Meng, N., Gehr, T.W., Boini, K.M., Li, P.L., Characterization and activation of NLRP3 inflammasomes in the renal medulla in mice. Kidney Blood Press. Res. 41:2 (2016), 208–221.
164. [164] Coll, R.C., Robertson, A.A., Chae, J.J., Higgins, S.C., Munoz-Planillo, R., Inserra, M.C., O'Neill, L.A., A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21:3 (2015), 248–255.
165. [165] Wang, F., Huang, L., Peng, Z.Z., Tang, Y.T., Lu, M.M., Peng, Y., Tao, L.J., Losartan inhibits LPS + ATP-induced IL-1beta secretion from mouse primary macrophages by suppressing NALP3 inflammasome. Pharmazie 69:9 (2014), 680–684.
166. [166] Ding, L.H., Liu, D., Xu, M., Liu, H., Wu, M., Tang, R.N., Liu, B.C., Enalapril inhibits tubulointerstitial inflammation and NLRP3 inflammasome expression in BSA-overload nephropathy of rats. Acta Pharmacol. Sin. 35:10 (2014), 1293–1301.
167. [167] Shirasuna, K., Karasawa, T., Usui, F., Kobayashi, M., Komada, T., Kimura, H., Takahashi, M., NLRP3 deficiency improves angiotensin II-induced hypertension but not fetal growth restriction during pregnancy. Endocrinology 156:11 (2015), 4281–4292.
168. [168] Dalekos, G.N., Elisaf, M., Bairaktari, E., Tsolas, O., Siamopoulos, K.C., Increased serum levels of interleukin-1 beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients?. J. Lab. Clin. Med. 129:3 (1997), 300–308.
169. [169] Rabkin, S.W., The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat. Clin. Pract. Cardiovasc. 6:3 (2009), 192–199.
170. [170] Dorffel, Y., Latsch, C., Stuhlmuller, B., Schreiber, S., Scholze, S., Burmester, G.R., Scholze, J., Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34:1 (1999), 113–117.
171. [171] Li, Q.Z., Deng, Q., Li, J.Q., Yi, G.H., Zhao, S.P., Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clin. Chim. Acta 355:1–2 (2005), 131–136.
172. [172] Yamamoto, T., Kimura, T., Ota, K., Shoji, M., Inoue, M., Ohta, M., Abe, K., Effects of interleukin-1 beta on blood pressure, thermoregulation, and the release of vasopressin, ACTH and atrial natriuretic hormone. Tohoku J. Exp. Med. 173:2 (1994), 231–245.
173. [173] Loughrey, J.P., Laffey, J.G., Moore, B.J., Lynch, F., Boylan, J.F., McLoughlin, P., Interleukin-1 beta rapidly inhibits aortic endothelium-dependent relaxation by a DNA transcription-dependent mechanism. Crit. Care Med. 31:3 (2003), 910–915.
174. [174] Jimenez-Altayo, F., Briones, A.M., Giraldo, J., Planas, A.M., Salaices, M., Vila, E., Increased superoxide anion production by interleukin-1 beta impairs nitric oxide-mediated relaxation in resistance arteries. J. Pharmacol. Exp. Ther. 316:1 (2006), 42–52.
175. [175] Dorrance, A.M., Interleukin 1-beta (IL-1beta) enhances contractile responses in endothelium-denuded aorta from hypertensive, but not normotensive, rats. Vascul. Pharmacol. 47:2–3 (2007), 160–165.
176. [176] Vinh, A., Chen, W., Blinder, Y., Weiss, D., Taylor, W.R., Goronzy, J.J., Guzik, T.J., Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 122:24 (2010), 2529–2537.
177. [177] Ellmeier, W., Sawada, S., Littman, D.R., The regulation of CD4 and CD8 coreceptor gene expression during T cell development. Annu. Rev. Immunol. 17 (1999), 523–554.
178. [178] Idris-Khodja, N., Mian, M.O., Paradis, P., Schiffrin, E.L., Dual opposing roles of adaptive immunity in hypertension. Eur. Heart J. 35:19 (2014), 1238–1244.
179. [179] Trott, D.W., Harrison, D.G., The immune system in hypertension. Adv. Physiol. Educ. 38:1 (2014), 20–24.
180. [180] Zhang, J., Crowley, S.D., Role of T lymphocytes in hypertension. Curr. Opin. Pharmacol. 21 (2015), 14–19.
181. [181] Herrera, J., Ferrebuz, A., MacGregor, E.G., Rodriguez-Iturbe, B., Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J. Am. Soc. Nephrol.: JASN 17:12 Suppl. 3 (2006), S218–S225.
182. [182] Bravo, Y., Quiroz, Y., Ferrebuz, A., Vaziri, N.D., Rodriguez-Iturbe, B., Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension, American journal of physiology. Renal Physiol. 293:2 (2007), F616–23.
183. [183] Muller, D.N., Shagdarsuren, E., Park, J.K., Dechend, R., Mervaala, E., Hampich, F., Luft, F.C., Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am. J. Pathol. 161:5 (2002), 1679–1693.
184. [184] Seaberg, E.C., Munoz, A., Lu, M., Detels, R., Margolick, J.B., Riddler, S.A., Multicenter, A.C.S., Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 19:9 (2005), 953–960.
185. [185] Bergersen, B.M., Sandvik, L., Dunlop, O., Birkeland, K., Bruun, J.N., Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur. J. Clin. Microbiol. Infect. Dis. 22:12 (2003), 731–736.
186. [186] White, F.N., Grollman, A., Autoimmune factors associated with infarction of the kidney. Nephron 1 (1964), 93–102.
187. [187] Okuda, T., Grollman, A., Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex. Rep. Biol. Med. 25:2 (1967), 257–264.
188. [188] Ebringer, A., Doyle, A.E., Raised serum IgG levels in hypertension. Br. Med. J. 2:5702 (1970), 146–148.
189. [189] Hilme, E., Herlitz, H., Soderstrom, T., Hansson, L., Increased secretion of immunoglobulins in malignant hypertension. J. Hypertens. 7:2 (1989), 91–95.
190. [190] Chen, C.M., Schachter, D., Elevation of plasma immunoglobulin A in the spontaneously hypertensive rat. Hypertension 21:5 (1993), 731–738.
191. [191] Bataillard, A., Freiche, J.C., Vincent, M., Sassard, J., Touraine, J.L., Antihypertensive effect of neonatal thymectomy in the genetically hypertensive LH rat. Thymus 8:6 (1986), 321–330.
192. [192] Guzik, T.J., Hoch, N.E., Brown, K.A., McCann, L.A., Rahman, A., Dikalov, S., Harrison, D.G., Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204:10 (2007), 2449–2460.
193. [193] Mattson, D.L., Lund, H., Guo, C., Rudemiller, N., Geurts, A.M., Jacob, H., Genetic mutation of recombination activating gene 1 in Dahl salt-sensitive rats attenuates hypertension and renal damage. Am. J. Physiol. Regul. Integr. Comp. Physiol. 304:6 (2013), R407–14.
194. [194] Crowley, S.D., Song, Y.S., Lin, E.E., Griffiths, R., Kim, H.S., Ruiz, P., Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298:4 (2010), R1089–R1097, 10.1161/HYPERTENSIONAHA.110.162941.
195. [195] Itani, H.A., McMaster, W.G. Jr., Saleh, M.A., Nazarewicz, R.R., Mikolajczyk, T.P., Kaszuba, A.M., Guzik, T.J., Activation of human T cells in hypertension: studies of humanized mice and hypertensive humans. Hypertension 68:1 (2016), 123–132.
196. [196] O'Shea, J.J., Paul, W.E., Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327:5969 (2010), 1098–1102.
197. [197] Roark, C.L., Simonian, P.L., Fontenot, A.P., Born, W.K., O'Brien, R.L., gammadelta T cells: an important source of IL-17. Curr. Opin. Immunol. 20:3 (2008), 353–357.
198. [198] Gutcher, I., Becher, B., APC-derived cytokines and T cell polarization in autoimmune inflammation. J. Clin. Invest. 117:5 (2007), 1119–1127.
199. [199] Kamat, N.V., Thabet, S.R., Xiao, L., Saleh, M.A., Kirabo, A., Madhur, M.S., McDonough, A.A., Renal transporter activation during angiotensin-II hypertension is blunted in interferon-gamma-/- and interleukin-17A-/- mice. Hypertension 65:3 (2015), 569–576.
200. [200] Madhur, M.S., Lob, H.E., McCann, L.A., Iwakura, Y., Blinder, Y., Guzik, T.J., Harrison, D.G., Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55:2 (2010), 500–507.
201. [201] Amador, C.A., Barrientos, V., Pena, J., Herrada, A.A., Gonzalez, M., Valdes, S., Michea, L., Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 63:4 (2014), 797–803.
202. [202] Zhang, J.D., Patel, M.B., Song, Y.S., Griffiths, R., Burchette, J., Ruiz, P., Crowley, S.D., A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ. Res. 110:12 (2012), 1604–1617.
203. [203] Shao, J., Nangaku, M., Miyata, T., Inagi, R., Yamada, K., Kurokawa, K., Fujita, T., Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42:1 (2003), 31–38.
204. [204] Kossmann, S., Schwenk, M., Hausding, M., Karbach, S.H., Schmidgen, M.I., Brandt, M., Wenzel, P., Angiotensin II-induced vascular dysfunction depends on interferon-gamma-driven immune cell recruitment and mutual activation of monocytes and NK-cells. Arterioscler. Thromb. Vasc. Biol. 33:6 (2013), 1313–1319.
205. [205] Davidson, T.S., Shevach, E.M., Polyclonal Treg cells modulate T effector cell trafficking. Eur. J. Immunol. 41:10 (2011), 2862–2870.
206. [206] Viel, E.C., Lemarie, C.A., Benkirane, K., Paradis, P., Schiffrin, E.L., Immune regulation and vascular inflammation in genetic hypertension. Am. J. Physiol. Heart Circ. Physiol. 298:3 (2010), H938–44.
207. [207] Barhoumi, T., Kasal, D.A., Li, M.W., Shbat, L., Laurant, P., Neves, M.F., Schiffrin, E.L., T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57:3 (2011), 469–476.
208. [208] Kasal, D.A., Barhoumi, T., Li, M.W., Yamamoto, N., Zdanovich, E., Rehman, A., Schiffrin, E.L., T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 59:2 (2012), 324–330.
209. [209] Mian, M.O., Barhoumi, T., Briet, M., Paradis, P., Schiffrin, E.L., Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J. Hypertens. 34:1 (2016), 97–108.
210. [210] Galan, M., Salaices, M., T-regulatory cells and vascular function: the importance of their immunosuppressive action in hypertensive disease. J. Hypertens. 34:1 (2016), 36–38.
211. [211] Matrougui, K., Abd Elmageed, Z., Kassan, M., Choi, S., Nair, D., Gonzalez-Villalobos, R.A., Partyka, M., Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am. J. Pathol. 178:1 (2011), 434–441.
212. [212] Serre, K., Silva-Santos, B., Molecular mechanisms of differentiation of murine pro-Inflammatory gammadelta T cell subsets. Front. Immunol., 4, 2013, 431.
213. [213] Li, Y., Wu, Y., Zhang, C., Li, P., Cui, W., Hao, J., Du, J., gammadeltaT Cell-derived interleukin-17A via an interleukin-1beta-dependent mechanism mediates cardiac injury and fibrosis in hypertension. Hypertension 64:2 (2014), 305–314.
214. [214] Saleh, M.A., Norlander, A.E., Madhur, M.S., Inhibition of interleukin-17A, but not interleukin-17F, signaling lowers blood pressure, and reduces end-organ inflammation in angiotensin II-induced hypertension. JACC: Basic Transl. Sci., 2016, 10.1016/j.jacbts.2016.07.009.
215. [215] Russell, J.H., Ley, T.J., Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20 (2002), 323–370.
216. [216] Fong, T.A., Mosmann, T.R., Alloreactive murine CD8+ T cell clones secrete the Th1 pattern of cytokines. J. Immunol. 144:5 (1990), 1744–1752.
217. [217] Youn, J.C., Yu, H.T., Lim, B.J., Koh, M.J., Lee, J., Chang, D.Y., Park, S., Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension 62:1 (2013), 126–133.
218. [218] Trott, D.W., Thabet, S.R., Kirabo, A., Saleh, M.A., Itani, H., Norlander, A.E., Harrison, D.G., Oligoclonal CD8+ T cells play a critical role in the development of hypertension. Hypertension 64:5 (2014), 1108–1115.
219. [219] Maddaly, R., Pai, G., Balaji, S., Sivaramakrishnan, P., Srinivasan, L., Sunder, S.S., Paul, S.F., Receptors and signaling mechanisms for B-lymphocyte activation, proliferation and differentiation–insights from both in vivo and in vitro approaches. FEBS Lett. 584:24 (2010), 4883–4894.
220. [220] Chan, C.T., Sobey, C.G., Lieu, M., Ferens, D., Kett, M.M., Diep, H., Drummond, G.R., Obligatory role for B cells in the development of angiotensin II-dependent hypertension. Hypertension 66:5 (2015), 1023–1033.
221. [221] Tipton, A.J., Baban, B., Sullivan, J.C., Female spontaneously hypertensive rats have greater renal anti-inflammatory T lymphocyte infiltration than males, American journal of physiology. Regul. Integr. Comp. Physiol. 303:4 (2012), R359–67.
222. [222] Brinson, K.N., Elmarakby, A.A., Tipton, A.J., Crislip, G.R., Yamamoto, T., Baban, B., Sullivan, J.C., Female SHR have greater blood pressure sensitivity and renal T cell infiltration following chronic NOS inhibition than males, American journal of physiology. Regul. Integr. Comp. Physiol. 305:7 (2013), R701–10.
223. [223] Zimmerman, M.A., Baban, B., Tipton, A.J., O'Connor, P.M., Sullivan, J.C., Chronic ANG II infusion induces sex-specific increases in renal T cells in Sprague-Dawley rats. Am. J. Physiol. Renal Physiol. 308:7 (2015), F706–12.
224. [224] Tipton, A.J., Baban, B., Sullivan, J.C., Female spontaneously hypertensive rats have a compensatory increase in renal regulatory T cells in response to elevations in blood pressure. Hypertension 64:3 (2014), 557–564.
225. [225] Ji, H., Zheng, W., Li, X., Liu, J., Wu, X., Zhang, M.A., Sandberg, K., Sex-specific T-cell regulation of angiotensin II-dependent hypertension. Hypertension 64:3 (2014), 573–582.
226. [226] Pollow, D.P., Uhrlaub, J., Romero-Aleshire, M.J., Sandberg, K., Nikolich-Zugich, J., Brooks, H.L., Hay, M., Sex differences in T-lymphocyte tissue infiltration and development of angiotensin II hypertension. Hypertension 64:2 (2014), 384–390.
227. [227] Xia, J., Fang, M., Wu, X., Yang, Y., Yu, L., Xu, H., Xu, Y., A2b adenosine signaling represses CIITA transcription via an epigenetic mechanism in vascular smooth muscle cells. Biochim. Biophys. Acta 1849:6 (2015), 665–676.
228. [228] Buttice, G., Miller, J., Wang, L., Smith, B.D., Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ. Res. 98:4 (2006), 472–479.
229. [229] Kwak, B., Mulhaupt, F., Veillard, N., Pelli, G., Mach, F., The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med. Wkly. 131:3–4 (2001), 41–46.
230. [230] Dziarmaga, A., Hueber, P.A., Iglesias, D., Hache, N., Jeffs, A., Gendron, N., Goodyer, P., Neuronal apoptosis inhibitory protein is expressed in developing kidney and is regulated by PAX2. Am. J. Physiol.—Renal 291:4 (2006), F913–F920.
231. [231] Moreno, L., McMaster, S.K., Gatheral, T., Bailey, L.K., Harrington, L.S., Cartwright, N., Mitchell, J.A., Nucleotide oligomerization domain 1 is a dominant pathway for NOS2 induction in vascular smooth muscle cells: comparison with Toll-like receptor 4 responses in macrophages. Br. J. Pharmacol. 160:8 (2010), 1997–2007.
232. [232] Kanno, S., Nishio, H., Tanaka, T., Motomura, Y., Murata, K., Ihara, K., Hara, T., Activation of an innate immune receptor, Nod1, accelerates atherogenesis in Apoe-/- mice. J. Immunol. 194:2 (2015), 773–780.
233. [233] Delgado, C., Ruiz-Hurtado, G., Gomez-Hurtado, N., Gonzalez-Ramos, S., Rueda, A., Benito, G., Fernandez-Velasco, M., NOD1, a new player in cardiac function and calcium handling. Cardiovasc. Res. 106:3 (2015), 375–386.
234. [234] Motomura, Y., Kanno, S., Asano, K., Tanaka, M., Hasegawa, Y., Katagiri, H., Yamasaki, S., Identification of pathogenic cardiac CD11c+ macrophages in nod1-mediated acute coronary arteritis. Arterioscler. Thromb. Vasc. Biol. 35:6 (2015), 1423–1433.
235. [235] Liu, H.Q., Zhang, X.Y., Edfeldt, K., Nijhuis, M.O., Idborg, H., Back, M., Yan, Z.Q., NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 33:9 (2013), 2193–2201.
236. [236] Sun, J., Ding, Y., NOD2 agonist promotes the production of inflammatory cytokines in VSMC in synergy with TLR2 and TLR4 agonists. Sci. World J., 2012, 2012, 607157.
237. [237] Yazdanyar, S., Nordestgaard, B.G., NOD2/CARD15 genotype, cardiovascular disease and cancer in 43 600 individuals from the general population. J. Intern. Med. 268:2 (2010), 162–170.